Seeking Alpha

TREMFYA® (guselkumab) achieves U.S. approval for subcutaneous induction in adults with ulcerative colitis, now the first and only IL-23 inhibitor with a fully subcutaneous regimen

TREMFYA ® offers the flexibility of self-administration from the start of treatment, building on the prior approval of subcutaneous induction in Crohn's disease TREMFYA ® achieved significant rates of ...
Nasdaq

TREMFYA® (guselkumab) demonstrates impressive results across biologic-naïve and biologic-refractory patients in Crohn's disease and ulcerative colitis

TREMFYA® is the only IL-23 inhibitor to demonstrate superiority to ustekinumab in the overall population of patients with Crohn's disease, inclusive of those who are biologic-naïve and ...
WebMD

Tremfya: First Fully Under-the-Skin IL-23 Inhibitor Shot Approved for Ulcerative Colitis and Crohn’s Disease

What Is Tremfya, and Why Does It Matter? Tremfya (guselkumab) is a lab-made, dual-acting antibody medication that reduces inflammation by targeting the interleukin-23 (IL-23) protein and blocking a ...